

***徐鴻智醫師**

所有發表期刊論文

- (1). Chou WC, Lu CH, Lin G, Hong YS, Chen PT, **Hsu HC**, Chen JS, Yeh KY, Wang HM, Liaw CC*. Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients' experiences from a single medical center. Support Care Cancer. 2007 Oct; 15(10):1185-90. Epub 2007 Mar 14.
共同作者, 原始論著
- (2). **Hsu HC**, Chang HK, Lin YC, Hseu S, Chen JS, Yang TS, Wang HM, Shen WC*. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. Chang Gung Med J. 2009 Jan-Feb; 32(1):33-41.
第一作者, 原始論著
- (3). Shen WC, Yang TS, **Hsu HC**, Chen JS*. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer. Chang Gung Med J. 2011 Nov-Dec; 34(6):590-8.
共同作者, 原始論著
- (4). Chen JS, Chen YY, Huang JS, Yeh KY, Chen PT, Shen WC, **Hsu HC**, Lin YC, Wang HM*. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer. 2012 Jan; 15(1):49-55.
共同作者, 原始論著
- (5). Wu CE, **Hsu HC**, Shen WC, Lin YC, Wang HM, Chang JW, Chen JS*. Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis. Chang Gung Med J. 2012 Sep-Oct; 35(5):420-7.
共同作者, 原始論著
- (6). **Hsu HC**, Lin HC, Hsieh CH, Wang HM, Huang CY, Wu MH, Tseng CP*. A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta. 2013 Apr 18; 419: 77-84.
第一作者, 原始論著
- (7). **Hsu HC**, Chou WC, Shen WC, Wu CE, Chen JS, Liao CT, Lin YC; Yang TS*. Efficacy of Postoperative Oxaliplatin- or Irinotecan-based Chemotherapy after Curative Resection of Synchronous Liver Metastases from Colorectal Cancer. Anticancer Res. 2013 Aug; 33(8):3317-25.
第一作者, 原始論著
- (8). **Hsu HC**, Liu YS, Tseng KC, Hsu CL, Liang Y, Yang TS, Chen JS, Tang RP, Chen SJ*,

Chen HC* .Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis. 2013 Nov;28(11):1535-46

第一作者, 原始論著

(9). **Hsu HC**, Liu YS, Tseng KC, Chen HC*, Chen SJ*. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer. Biomedicine & Pharmacotherapy 2013 Oct;67(8):791-9.

第一作者, 原始論著